Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 12, 2015

View Archived Issues

Otsuka Pharmaceutical profiles progress of second quarter 2015

Genetic factors modify clinical onset of Huntington's disease

AbbVie and Reata present NO production inhibitors

Nabriva divulges mutilin derivatives

Confluence Life Sciences patents ITK inhibitors

Millenium presents PIK3C3 inhibitors

Cardioxyl Pharmaceuticals patents HNO donors

Phase I study investigates ADCT-301 for relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma

Allogenic MPCs show safety in HF patients

Immune Design and Merck & Co. collaborate to study immunotherapies with Keytruda

Gamida Cell reaches agreements on phase III trial design for NiCord

Relypsa signs new patiromer agreements

Novavax reports phase II results for RSV vaccine in older adults

EEC announced between Intrexon and Synthetic Biologics

Galapagos reports 24-week data from the phase IIb DARWIN 2 trial

Adynxx reports positive results for phase IIb study of AYX-1

Editas Medicine raises funds to advance genome editing platform

Intrexon to acquire insect control solutions company Oxitec

Mallinckrodt to acquire photopheresis company Therakos

FDA accepts La Jolla's IND for phase I study of LJPC-401

InSite Vision receives second acquisition offer, following agreement with QLT

IL-1alpha blockade shows promise for the treatment of type 2 diabetes

DSMB recommends continuation of phase I trial of ContraFect's CF-301

Janssen Biotech enters license agreement for Alligator's ADC-1013

Janssen starts phase III trial of ustekinumab in non-radiographic axial spondyloarthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...